NCT02680574: A reported trial by Akebia Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02680574 |
|---|---|
| Title | Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 29, 2016 |
| Completion date | June 18, 2020 |
| Required reporting date | June 18, 2023, midnight |
| Actual reporting date | April 25, 2022 |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |